ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Eculizumab Dose Reduction Is Safe by Monitoring Eculizumab Pre-Dose Level and Functional Complement Assays.

M. Gelens,1 T. Havenith,2 J. Damoiseaux,3 M. Christiaans.1

1Internal Medicine, MUMC, Maastricht, Netherlands
2Clinical Pharmacy, MUMC, Maastricht, Netherlands
3Central Diagnostic Laboratory, MUMC, Maastricht, Netherlands

Meeting: 2017 American Transplant Congress

Abstract number: B167

Keywords: Hemolytic-uremic syndrome, Humanized antibodies, Kidney transplantation, Recurrence

Session Information

Session Name: Poster Session B: Kidney Complications II

Session Type: Poster Session

Date: Sunday, April 30, 2017

Session Time: 6:00pm-7:00pm

 Presentation Time: 6:00pm-7:00pm

Location: Hall D1

Background & aims: Untreated atypical haemolytic syndrome (aHUS) leads to ESRD and may recur after renal transplantation. Eculizumab (Ecu), a humanized antibody inhibiting terminal C5 complement, is an expensive drug ($400,000,-/yr/pat) approved for treatment of aHUS and prevention of recurrence of aHUS posttransplant. At a serum level of Ecu > 50 ug/mL C5 complement is totally blocked1 and this is reflected in a suppressed functional complement assay (CH50<10%, AP50<10%)2.

We present a renal transplant patient treated by Eculizumab in whom Ecu dose could safely be reduced by monitoring Ecu pre-dose levels and functional complement assays.

Methods: Our patient had aHUS postpartum (Factor H mutation) and received a kidney transplantation 3 years later. Ecu was started for prevention of recurrence at the recommended dosing schedule (maintenance dose 1200mg q14days). After 6 months, the patient repeatedly experienced during and shortly after the infusion of Ecu 1200mg complaints of nausea, headache, and upper legs pain. To monitor the possibility and safety of dose reduction, pre-dose Ecu level, CH50/AP50 were measured. Dose-adjustments were made, guided by pre-dose Ecu level, CH50/AP50<10%. Adjustments were checked in steady state after at least 4 dose intervals.

Results: At 1200mg q14days, Ecu pre-dose level was >250 ug/mL with suppressed CH50 (1%) and AP50 (2%) . Dose reduction by 25% (to 900mg q14days) resulted in disappearance of her complaints with still 'elevated' pre-dose level and suppressed CH50 and AP50. Further dose reduction was performed by increasing dosing interval. Ecu 900mg q21days still resulted in a “high pre-dose level+ (± 180 ug/ml). At an Ecu dose of 900mg q28days, the pre-dose level was 62 mg/ml, with still suppressed CH50 (1%)/AP50 (3%) without any clinical or laboratory sign of aHUS activity. This 63.5% Ecu dose reduction (1200mg q14days to 900mg q28days) results for this patient into a saving of $250,000.- pro year on Ecu medication costs!

Conclusion: 1. Ecu has dose-related reversible side-effects. 2. Dose reduction improves patients QoL (no side-effects, larger dosing interval). 3. Dose reduction >60% is possible under monitoring of Ecu pre-dose level and safety/efficacy parameters reducing costs by $250,000.- pro year.

1. Legendre CM, et al. N Engl J Med 2013; 368:2169

2. Peffault de Latour R, et al. Blood. 2015 Jan 29;125(5):775.

CITATION INFORMATION: Gelens M, Havenith T, Damoiseaux J, Christiaans M. Eculizumab Dose Reduction Is Safe by Monitoring Eculizumab Pre-Dose Level and Functional Complement Assays. Am J Transplant. 2017;17 (suppl 3).

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Gelens M, Havenith T, Damoiseaux J, Christiaans M. Eculizumab Dose Reduction Is Safe by Monitoring Eculizumab Pre-Dose Level and Functional Complement Assays. [abstract]. Am J Transplant. 2017; 17 (suppl 3). https://atcmeetingabstracts.com/abstract/eculizumab-dose-reduction-is-safe-by-monitoring-eculizumab-pre-dose-level-and-functional-complement-assays/. Accessed May 9, 2025.

« Back to 2017 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences